These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 1350507

  • 1. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
    Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR.
    Cancer Res; 1992 Jun 01; 52(11):3029-34. PubMed ID: 1350507
    [Abstract] [Full Text] [Related]

  • 2. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
    Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T.
    J Clin Invest; 1995 May 01; 95(5):2205-14. PubMed ID: 7738186
    [Abstract] [Full Text] [Related]

  • 3. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC.
    Cancer Res; 1993 Nov 01; 53(21):5225-32. PubMed ID: 8106143
    [Abstract] [Full Text] [Related]

  • 4. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):391-7. PubMed ID: 11976833
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
    Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts T, Smit JJ, Borst P.
    Cancer Res; 1990 Mar 15; 50(6):1779-85. PubMed ID: 1968359
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM.
    Cancer Res; 1987 Oct 15; 47(20):5455-60. PubMed ID: 2888532
    [Abstract] [Full Text] [Related]

  • 9. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB, Beck WT, Trent JM.
    Cancer Res; 1988 Jan 15; 48(2):393-8. PubMed ID: 2891436
    [Abstract] [Full Text] [Related]

  • 10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 15; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 11. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I, Brisson C, Fabre M, Bergerat JP, Rebel G.
    Anticancer Res; 2008 Jul 15; 28(1A):55-68. PubMed ID: 18383825
    [Abstract] [Full Text] [Related]

  • 12. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen.
    Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, Kenney S, Keller J, Boyd MR.
    Anticancer Res; 1992 Jul 15; 12(4):1035-53. PubMed ID: 1503399
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM, Goldenberg S, Gottesman MM, Hait WN.
    Cancer Res; 1994 Feb 01; 54(3):730-7. PubMed ID: 7905786
    [Abstract] [Full Text] [Related]

  • 14. The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model.
    Ujhazy P, Chen YF, Fredericks W, Ho RL, Mihich E, Baker RM, Ehrke MJ.
    Cancer Commun; 1990 Feb 01; 2(5):181-8. PubMed ID: 1973358
    [Abstract] [Full Text] [Related]

  • 15. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG, Tom C, McGregor JR, Slade L, Samlowski WE.
    Cancer Res; 1990 Sep 15; 50(18):5931-6. PubMed ID: 1975512
    [Abstract] [Full Text] [Related]

  • 16. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M.
    Anticancer Res; 1994 Sep 15; 14(5A):1995-2003. PubMed ID: 7847840
    [Abstract] [Full Text] [Related]

  • 17. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT, Berek JS, Bonavida B.
    Gynecol Oncol; 1993 Feb 15; 48(2):214-20. PubMed ID: 8428693
    [Abstract] [Full Text] [Related]

  • 18. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells.
    Mazzanti R, Croop JM, Gatmaitan Z, Budding M, Steiglitz K, Arceci R, Arias IM.
    Oncol Res; 1992 Feb 15; 4(8-9):359-65. PubMed ID: 1362504
    [Abstract] [Full Text] [Related]

  • 19. Evidence for multidrug-resistant cells in human tumor cell populations.
    Shoemaker RH, Curt GA, Carney DN.
    Cancer Treat Rep; 1983 Oct 15; 67(10):883-8. PubMed ID: 6313186
    [Abstract] [Full Text] [Related]

  • 20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.